임플란트의 collar design이 변연골과 연조직에 미치는 영향

유현상,강선녀,정창모,윤미정,허중보,전영찬 대한치과보철학회 2012 대한치과보철학회지 Vol.50 No.1

연구 목적: 임플란트 경부가 잘 설계된 경우 양호한 연조직 반응을 통해 변연골을 보존하는데 도움이 된다. 본 실험에서는 연, 경조직 경계부에 가장 가까이 위치하는 임플란트의 collar design이 변연골 변화와 연조직 반응에 미치는 영향을 동물실험을 통해 알아보고자 하였다. 연구 재료 및 방법: 2마리의 건강한 Beagle dog에 임플란트 collar design만 다른 두 종류의 임플란트(Neobiotech Co. Seoul, Korea)를 식립하였다. Collar에 bevel 을 부여한 군(Bevel 군)과 "S"자 형태를 부여한 군(Bioseal 군)으로 나누어 마리 당 7개, 군당 7개, 총 14개의 임플란트를 무작위로 식립한 후 Healing abutment를 즉시 체결하였다. 디지털 표준구내 방사선사진을 이용해 4주 간격으로 총 12주간 근원심 변연골 변화를 관찰하였고, 12주에 희생하여 조직학적 분석을 통해 협설 변연골 흡수 및 임플란트 주변 연조직 반응을 평가하였다. Mann-Whitney test를 통해 동일한 방사선 사진 촬영 시점에서 근원심 변연골 변화량 및 조직계측치를 군 간 비교하였고, Kruskal-Wallis test를 통해 방사선 사진상 근원심 변연골 변화량이 시간에 따른 차이가 있는지 군 내 분석 한 후 Duncan test를 통해 사후 검증하였다(α=.05). 결과: 방사선학적 분석 결과 각 촬영 시점에서 두 군간 근원심 변연골 변화량의 차이를 보이지 않았다(P>.05). 군 내에서 시간에 따른 근원심 변연골의 흡수량을 분석한 결과 Bevel 군에서는 시간에 따른 차이를 보이지 않았으나 (P>.05), Bioseal 군에서는 시간에 따른 차이를 보였으며, 4주및8주와 비교했을 때 12주에서 변연골의 증가를 보였다(P<.05). 조직학적 분석 결과 협설측 변연골 흡수량에서 두 군간 차이를 보이지 않았으나 (P>.05), Bevel 군에 비해 Bioseal 군에서 더 견고한 결합조직부착을 관찰할 수 있었으며, 생물학적 폭경의 값은 두 집단 간 차이를 보이지 않은 반면에 (P>.05), 접합상피부착은 Bevel 군에서 유의하게 길었고, 결합조직부착은 Bioseal 군에서 더 길게 나타났다(P<.05). 결론: Bevel 군에 비해 Bioseal 군에서 결합조직부착은 길게 형성된 반면에 접합상피부착은 더 짧게 나타났으며, 생물학적 폭경과 초기 변연골 흡수에는 차이가 없음을 알 수 있었다. 연조직 반응의 차이가 실제 기능하중 하에서 변연골 변화에 미치는 영향에 대해서 향후 연구가 필요할 것으로 생각된다. PURPOSE. The purpose of this study was to investigate the effects of implant collar design on marginal bone change and soft tissue response by an animal test. MATERIALS AND METHODS. Two types of Implant (Neobiotech Co. Seoul, Korea) that only differs in collar design were planted on two healthy Beagle dogs. The implants were divided into two groups, the first group with a beveled collar (Bevel Group) and the second group with "S" shaped collar (Bioseal group). Standardized intraoral radiographs were used to investigate the mesio-distal change of the marginal bone. Histological analysis was done to evaluate the bucco-lingual marginal bone resorption and the soft tissue response adjacent to the implant. Mann-Whitney test was done to compare the mesio-distal marginal bone change at equivalent time for taking the radiographs and the tissue measurements between the groups. RESULTS. Radiographic and histological analysis showed that there was no difference in marginal bone change between the two groups (P>.05). Histological analysis showed Bioseal group had more rigid connective tissue attachment than the Bevel group. There was no difference in biological width (P>.05). Bevel group showed significantly longer junctional epithelium attachment and Bioseal group showed longer connective tissue attachment (P<.05). CONCLUSION. For three months there were no differences in marginal bone change between the Bevel group and the Bioseal group. As for the soft tissue adjacent to the implant, Bioseal group showed longer connective tissue attachment while showing shorter junctional epithelium attachment. There were no differences in biologic width.

부착성 동물세포의 Scale-up을 위한 방법의 개발

김승모,송상호,최명락,유은정,임현수 여수대학교 1997 論文集 Vol.11 No.2

This study was a protocol of serial propagation for anchorage-dependent animal cell. Vero. by the optimization of trypsin and EDTA concentration in T-25 flask. Commen enzymetic treatment in PBS solution has been modified for a high degree of cell datachment from T-25 flask and for transfer of a maximum number of viable cells from one culture to the next during the scale up process. Culture of Vero cells were washed with Dulbecco's modified Eagle's medium(DMEM) and then exposed to DMEM containing trypsin(0.025%) and EDTA(0.16%). Up to 90% of cells detached from bottom of flask and the viability of cells was greater than 93%. The protocol using the developed method was successfully applied to the next 10 times scale up process. Consequently, the developed method changed multiple steps of processes to one step, so it promised th easy scale-up and low cost demand of animal cell culture.

진행성 비소세포폐암의 이차항암화학요법으로서 Docetaxel 단독요법의 성적

강현모,이정은,장필순,이연선,권선중,안진영,정성수,김주옥,김선영 충남대학교 암연구소 2006 암연구소 업적집 Vol.5 No.-

Background : The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second -line chemotherapy, for which Docetaxel (Taxotere^(?)) has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum-based chemotherapy. Methods : Thirty one patients with non-small-cell lung cancer, who had failed first line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either 75 mg/㎡ or 100 mg/㎡, with routine premedication every three weeks. Results : Fourteen patients (45.2%) had a partial response. The median survival and progression- free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age (< 60 years: 20.1 months vs. > 60 years: 6.6 months, p=0.0105) and the histological type (adenocarcinoma: 25.6 months vs. others: 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses. Conclusion : Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small-cell lung cancer who failed first line platinum -based chemotherapy. (Tuberc Respir DiS 2005: 58: 465-472)

진행성 비소세포폐암의 이차항암화학요법으로서 Docetaxel 단독요법의 성적

강현모,이정은,장필순,이연선,권선중,안진영,정성수,김주옥,김선영 충남대학교 암공동연구소 2006 암공동연구소 업적집 Vol.5 No.

Background : The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second -line chemotherapy, for which Docetaxel (Taxotere^(?)) has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum-based chemotherapy. Methods : Thirty one patients with non-small-cell lung cancer, who had failed first line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either 75 mg/㎡ or 100 mg/㎡, with routine premedication every three weeks. Results : Fourteen patients (45.2%) had a partial response. The median survival and progression- free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age (< 60 years: 20.1 months vs. > 60 years: 6.6 months, p=0.0105) and the histological type (adenocarcinoma: 25.6 months vs. others: 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses. Conclusion : Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small-cell lung cancer who failed first line platinum -based chemotherapy. (Tuberc Respir DiS 2005: 58: 465-472) 연구배경 : 일차항암화학요법 후에 생존의 이득을 얻었음에도 불구하고 비소세포폐암 환자들의 대다수가 결국은 재발하거나 진행성 병변을 보인다. 이에 저자들은 기존의 여러 연구에서 보고 된 구제요법으로서 docetaxel의 항암효과와 비교적 적은 독성의 결과를 바탕으로,platinum을 근거로 한 항암화학요법을 시행 밖았으나 개발되거나 진행된 비소세포폐암 환자들을 대상으로 docetaxel 단독요법의 치료효과와 부작용에 대하여 알아보고자 하였다. 방법 : 조직학적으로 비소세포폐암으로 진단을 받고 platinum을 근거로 한 항암화학요법을 받았으나 재발 또는 진행성 병변을 보인 31명의 환자들을 대상으로 docetaxel 75 mg/m² 또는 100 mg/m²을 3주마다 정주하였다. 임상기록을 통한 후향적인 방법으로 분석하였다. 결과 : 1) 재발 또는 진행성 병변을 보인 31명중 남녀 비는 24:7이고 중앙연령은 60세였다. 2) 반응평가로 완전 관해는 없었고 부분관해는 14명(45.2%), 불변이 10명(32.3%), 진행이 7명(22.6%)으로 전체적인 반응율은 45.2%이었다. 3)중앙생존기간은 12.5개월(95% 신뢰구간: 7.3개월 17.6개월) 이었고, 1년 생존율은 52%였다. 무진행생존기간의 중앙값은 3.0개월(95%신뢰구간: 1.6개월 -4.5개월)이며, 반응군에서의 중앙반응지속피간은 3.7개월(95% 신뢰구간: 3.0개월 - 4.4개월)이었다. 4) 60세 미만인 경우(20.1 months vs 6.6 months. p=0,0105), 조직학적 아형이 선암일 경우(25.6 months vs 7.9 months, 0=0.0055) 통계적으로 유의한 생존기간의 증가가 있었다. 5) 부작용으로 3도 이상의 백혈구 감소증은 12명(38.7%),호중구 감소증에 동반된 발열은 6명(19.3%),감염이 동반된 호중구 감소증은 4명(12.9%)에서 발생했다. 치료와 관련되어 1명이 사망하였다. 6) Docetaxel 용량에 따른 생존기간의 차이나 독성의 차이는 없었다. 결론 : Platinum을 근거로 하는 항암화학요법으로 치료받은 후 재발 또는 진행성 병변을 보이는 비소세포폐암환자들에게 docetaxel을 투여하는 것은 비교적 안전하고 효과적인 항암치료법으로 사료된다.

부산광역시 승용자동차 주행중 전신진동 및 소음도 평가

옥치상,모현주,정재열 高神大學校保健科學硏究所 1997 보건과학연구소보 Vol.7 No.-

There are many vibrations and noixes during vehicle use in urban although pavement road. Those are from engin vibarations, tire and wheel related vibrations. And the vibrations of vehicle use cause frequently las variation of road state. This study investivated the whole-body vibration and noise caused as variation of road state and speeds during automobile duiving in Pusan City, Korea Based on the results, exposure to whole body vibration and noise during vehicle use was higher at 70km/h than 50km/h in speed. On the floor of vehicle at speed 50km/h and 70km/h, the the mean values of energy equivalent acceleration and permissible exposure time by vebrational performance were 99.2cm/s²(1512.4 min), 200.3cm/s²(1939.5 min)in x axis ; 132.3cm/s²(1035.9 min),182.3cm/s²(1278.2 min) in y axis;87.1cm/s²(2774.6 min),234.8cm/s²(4196.4 min) in z axis, respectively. And on the seat of vehicle at speed 50km/h and 70km/hr,82.0cm/s²(597.1 min),63.2cm/s²(757.4 min), 157.2cm/s²(1286.8 min) in z axis, respectively. Permissible noise exposure time(PNET) caused during vehicle use were 80hr, 184hr in speed 50km/h and 57hr, 116hr in speed 70kn/h when doors were closed and open,respectively.

비소세포 폐암 환자의 이차 치료로서 Gemcitabine과 Vinorelbine 혼합 요법의 효과

장필순,강현모,이정은,권선중,안진영,이연선,정성수,김주옥,김선영 충남대학교 암공동연구소 2006 암공동연구소 업적집 Vol.5 No.

Background : Both gemcitabine and vinorelbine are effective anticancer drugs with mild toxicity on non-small cell lung cancer, and monotherapy of these drugs are effective as a second-line chemotherapy. The aim of this trial was to assess the response and toxicity of a combination of gemcitabine and vinorelbine in patients of previously treated for non-small cell lung cancer. Materials and Methods : 24 patients, initial stage III A/B,IV and previously treated with platinium and taxane based regimens, were enrolled from June 2000 to March 2004. The regimens consisted of vinorelbine 25mg/㎡ followed by an infusion of gemcitabine 1000mg/㎡ on day 1 and day 8 every three weeks. This course was repeated more than twice. Results : Twenty-four patients were analyzed for the response, survival rate, and toxicities. The overall response was 17% with a complete remission rate of 4%. The median time-to progression (TTP) was 3.1 months (95%, CI l-10months), and the survival time was 8.2 months (95%, CI 1-23 months). The grade 3/4 toxicities encountered were neutropenia (12.5%), anemia (0%), thrombocytopenia (0%). Non-hematological 3/4 toxicities were not observed. Conclusion : A combination of gemcitabine and vinorelbine in patients previously treated for non-small cell lung cancer provides a relatively good response rate, and a low toxicity profile. However, further study will be needed to confirm its effectiveness. (Tuberc Respir Dis 2005; 58: 344-351) 배경 : Gemcitabine, paditaxel, docetaxel, vinorelbine, ir-rinotecan 새로운 항종양제의 출현으로 일차 치료의효과가 증대 되고 있고 재발시에도 좋은 신체 활동도를 보이고 있어서 이차 치료의 대상군도 늘어나는 효과를 보이고 있다. 치료의 필요성은 증대 되고 있지만 현재까지 표준 치료가 확립되지 않은 상황에서 Gem-citabine과Vinorelbine모두 독성이 강하지 않아서 혼합 요법이 가능한 장점이 있고 비소세포 폐암에 대한효과도 입증이 되어있어서 본 연구는 반응이 없거나 반응을 보인후에 재발된 진행된 비소세포 폐암에 ge-mdtabine과 vinorelbine 흔합 요법을 시행하여서 치료 반응률과 생존율 그리고 부작용을 평가하였다. 대상 및 방법 :2000년 6월부터 2004년 3월까지 충남대학교병원에내원하여 진행성 비소세포 폐암 IIIA/IIIB, IV로 진단을 받고 일차 항암화학요법치료를 받은 환자중에 초기 치료에 반응이 없거나, 치료에 반응이 있었으나 병이 진행된 환자로 추적 관찰 기간이 6개월 이상인 환자를 대상으로 생존율과 반응률 그리고 독성을 분석하였다. 결과 : 총 치료 반응률은 17%. 반응 유지기간의 중앙값은 3.1개월(1-10개월)이었고 생존기간의 중앙값은 8.2개월 (1-23개월) 그리고 1년 생존율은 35%였다. 항암화학요법에 의한 독성은 3도 이상의 중성구 감소가 12%, 오심과 구토가 12.5% 였다. 결론 : 일차 치료에 반응이 없거나 재발한 비소세포 폐암환자의 이차 치료로 gemcitabine과 vinorelbine 혼합요법은 효과적이라고 생각되며 향후 3상 연구를 통한다른 약제와의 비교 연구가 필요하다고 생각된다.

抵當湯이 血栓症에 미치는 실험적 연구

田炳薰,任光模,鄭鉉雨,禹元洪,鄭遇悅 대한동의병리학회 1993 동의생리병리학회지 Vol.8 No.-

연구배경 : 뇌혈관계 질환이 우리나라의 높은 사망률을 차지하고 있고, 또한 혈전증에 활혈화어법을 대단히 많이 응용되고 있어 실증의 어혈증후군에 사용되는 저당탕으로 뇌혈관계 질환중의 하나인 혈전증이 "어혈" 의 범주에 속하는 지를 고찰할 필요가 있었다. 그리하여 본 연구는 저당탕을 임상에서 혈전증 치료에 응용할 수 있는지를 알아보기 위하여 실시하였다. 방법 : 저당탕 5첩분량(138.75g)을 100ml로 감압농축하여 0.2mg/kg의 endotoxin을 시로투여 1시간 후에 백서의 미정맥에 주입하고 4시간이 경과되면 urethane마취하에서 심장채혈 하였다. 결과 : 혈소판수는 대조군에 비하여 유의성 있게 증가하였고 protheombin time도 대조군에 대조군에 비하여 유의성 있는 단축을 보였으나 fibrinogen 량은 대조군에 비하여 증가를 하였지만 유의성은 보이지 않았다. 또한 전혈점도와 혈장점도는 대조군에 비하여 유의성 있는 감소를 보였다. 결론 : 저당탕이 혈전증에 미치는 영향은 유의한 것으로 나타났다. 그렇기 때문에 혈전증과 어혈과는 깊은 관련을 가지고 있어 저당탕이 뇌혈관 질환뿐만 아니라 어혈성 질환에 임상적으로 응용하면 보다 높은 치료효과를 거두리라 사려된다.

急速凝固한 高純度 Fe―C―Si合金중의 Carbide共晶의 過冷却凝固 시뮬레이션

김영직,서수정,안현모 成均館大學校 科學技術硏究所 1991 論文集 Vol.42 No.1

This paper decribes a study of the solidification simulation with supercooling of levitation melted and rapidly solidified high purity Fe--C-Si alloys with emphasis on carbide eutectic. Newly designed growth model of carbide eutectic is proposed. From the simulation model, calculated cooling curves are derived by means of a personal computer, and compared with experimental data. The results calculated are influenced remarkably by coefficient of heat tranfer(h), latent heat of solidification(L), growth rate constant(n) and range of temperature of mushy zone. After suitable choice of h, L, n and especially temperature range of mushy zone as 100K, experimental cooling curves are duplicated by calculated. As the cooling rate exceed about l0^3K/s, graphite crystal is not formed in the high purity Fe -C-Si melts.

비소세포 폐암 환자의 이차 치료로서 Gemcitabine과 Vinorelbine 혼합 요법의 효과

장필순,강현모,이정은,권선중,안진영,이연선,정성수,김주옥,김선영 충남대학교 암연구소 2006 암연구소 업적집 Vol.5 No.-

Background : Both gemcitabine and vinorelbine are effective anticancer drugs with mild toxicity on non-small cell lung cancer, and monotherapy of these drugs are effective as a second-line chemotherapy. The aim of this trial was to assess the response and toxicity of a combination of gemcitabine and vinorelbine in patients of previously treated for non-small cell lung cancer. Materials and Methods : 24 patients, initial stage III A/B,IV and previously treated with platinium and taxane based regimens, were enrolled from June 2000 to March 2004. The regimens consisted of vinorelbine 25mg/㎡ followed by an infusion of gemcitabine 1000mg/㎡ on day 1 and day 8 every three weeks. This course was repeated more than twice. Results : Twenty-four patients were analyzed for the response, survival rate, and toxicities. The overall response was 17% with a complete remission rate of 4%. The median time-to progression (TTP) was 3.1 months (95%, CI l-10months), and the survival time was 8.2 months (95%, CI 1-23 months). The grade 3/4 toxicities encountered were neutropenia (12.5%), anemia (0%), thrombocytopenia (0%). Non-hematological 3/4 toxicities were not observed. Conclusion : A combination of gemcitabine and vinorelbine in patients previously treated for non-small cell lung cancer provides a relatively good response rate, and a low toxicity profile. However, further study will be needed to confirm its effectiveness. (Tuberc Respir Dis 2005; 58: 344-351)

경막 내 colistimethate 투여로 치료한 다제 내성 cinetobacter baumannii 뇌실염

홍유아,유진홍,김진진,모은영,안건희,정희경,김진석,이현정,정미향,윤승배 대한감염학회 2009 감염과 화학요법 Vol.41 No.4

Acinetobacter species is a non-fermentative aerobic gram-negative coccobacillus that is an important pathogen found in nosocomial infections. Recently, multi-drug resistant Acinetobacter baumannii (MDR-AB) infections have been increasing and pose a serious problem. Most such infections present as bacteremia, pneumonia, or a wound infection; however, CNS infections are very rare. We herein present a case of ventriculitis caused by MDR-AB in a 37-year old man after a neurosurgical intervention. The patient was successfully treated with intrathecal colistimethate.